IBD Patients Willing to Accept High Medication Risks to Maintain Disease Remission

IBD Patients Willing to Accept High Medication Risks to Maintain Disease Remission
According to the results of a recent survey study published in The American Journal of Gastroenterology, patients with inflammatory bowel disease (IBD) reported they were willing to accept the fairly high risks of lymphoma and serious infections related with medical therapies to maintain remission and avoid disease relapse. The study is titled Inflammatory Bowel Disease Patients’ Willingness to Accept Medication Risk to Avoid Future Disease Relapse.” Crohn’s disease (CD) and ulcerative colitis (UC) are relapsing conditions with no known medical cure. Clinical trials and treatment guidelines emphasize early aggressive management in IBD, including the use of immunosuppressant medications or the addition of a biologic to an immunosuppressant medication (combination therapy), with the goal of preventing future complications. “Prior studies have demonstrated that patients are willing to accept relatively high risks of serious adverse events … to improve current symptoms of IBD,” wrote Meenakshi Bewtra, MD, MPH, PhD, from University of Pennsylvania, and colleagues according to a recent news release. “However, little is known about how much patients value future time in remission relative to future risks of [serious adv
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *